5T2T
| Crystal structure of Lymphocytic choriomeningitis mammarenavirus endonuclease bound to compound L742001 | 分子名称: | (2Z)-4-[1-benzyl-4-(4-chlorobenzyl)piperidin-4-yl]-2-hydroxy-4-oxobut-2-enoic acid, CHLORIDE ION, GLYCEROL, ... | 著者 | Saez-Ayala, M, Yekwa, E.L, Canard, B, Alvarez, K, Ferron, F. | 登録日 | 2016-08-24 | 公開日 | 2017-09-13 | 最終更新日 | 2024-01-17 | 実験手法 | X-RAY DIFFRACTION (1.967 Å) | 主引用文献 | Crystal structures ofLymphocytic choriomeningitis virusendonuclease domain complexed with diketo-acid ligands. IUCrJ, 5, 2018
|
|
5LTS
| Crystal structure of Lymphocytic choriomeningitis mammarenavirus endonuclease Mutant D118A | 分子名称: | CHLORIDE ION, GLYCEROL, RNA-directed RNA polymerase L, ... | 著者 | Saez-Ayala, M, Yekwa, E.L, Canard, B, Alvarez, K, Ferron, F. | 登録日 | 2016-09-07 | 公開日 | 2017-09-13 | 最終更新日 | 2024-01-17 | 実験手法 | X-RAY DIFFRACTION (2.51 Å) | 主引用文献 | Crystal structures ofLymphocytic choriomeningitis virusendonuclease domain complexed with diketo-acid ligands. IUCrJ, 5, 2018
|
|
5LTN
| Crystal structure of Lymphocytic choriomeningitis mammarenavirus endonuclease complexed with DPBA | 分子名称: | 2-4-DIOXO-4-PHENYLBUTANOIC ACID, CHLORIDE ION, DI(HYDROXYETHYL)ETHER, ... | 著者 | Saez-Ayala, M, Yekwa, E.L, Canard, B, Alvarez, K, Ferron, F. | 登録日 | 2016-09-07 | 公開日 | 2017-09-13 | 最終更新日 | 2024-01-17 | 実験手法 | X-RAY DIFFRACTION (1.88 Å) | 主引用文献 | Crystal structures of Lymphocytic choriomeningitis virusendonuclease domain complexed with diketo-acid ligands. Iucrj, 5, 2018
|
|
5LTF
| Crystal structure of Lymphocytic choriomeningitis mammarenavirus endonuclease complexed with catalytic ions | 分子名称: | MAGNESIUM ION, RNA-directed RNA polymerase L | 著者 | Saez-Ayala, M, Yekwa, E.L, Canard, B, Ferron, F. | 登録日 | 2016-09-06 | 公開日 | 2017-09-13 | 最終更新日 | 2024-01-17 | 実験手法 | X-RAY DIFFRACTION (2.43 Å) | 主引用文献 | Crystal structures ofLymphocytic choriomeningitis virusendonuclease domain complexed with diketo-acid ligands. IUCrJ, 5, 2018
|
|
7ZI1
| Crystal structure of dCK C4S-S74E mutant in complex with UDP and the dCKi1 inhibitor | 分子名称: | Deoxycytidine kinase, N-[3-[[4-(4-azanylpyrimidin-2-yl)-1,3-thiazol-2-yl]amino]-4-methyl-phenyl]-4-[(4-methylpiperazin-1-yl)methyl]benzamide, SODIUM ION, ... | 著者 | Saez-Ayala, M, Ben-Yaala, K, Betzi, S, Rebuffet, E, Morelli, X. | 登録日 | 2022-04-07 | 公開日 | 2023-06-07 | 最終更新日 | 2024-02-07 | 実験手法 | X-RAY DIFFRACTION (1.85 Å) | 主引用文献 | From a drug repositioning to a structure-based drug design approach to tackle acute lymphoblastic leukemia. Nat Commun, 14, 2023
|
|
7ZI6
| Crystal structure of dCK C4S-S74E mutant in complex with UDP and the OR0325 inhibitor | 分子名称: | 4-(4-azanylpyrimidin-2-yl)-N-[2-methyl-5-[4-[2-(4-methylpiperazin-1-yl)ethyl]phenyl]phenyl]-1,3-thiazol-2-amine, Deoxycytidine kinase, SODIUM ION, ... | 著者 | Saez-Ayala, M, Ben-Yaala, K, Betzi, S, Rebuffet, E, Morelli, X. | 登録日 | 2022-04-07 | 公開日 | 2023-06-07 | 最終更新日 | 2024-02-07 | 実験手法 | X-RAY DIFFRACTION (2.1 Å) | 主引用文献 | From a drug repositioning to a structure-based drug design approach to tackle acute lymphoblastic leukemia. Nat Commun, 14, 2023
|
|
7ZI5
| Crystal structure of dCK C4S-S74E mutant in complex with UDP and the OR0274 inhibitor | 分子名称: | 4-(4-azanylpyrimidin-2-yl)-N-[2-methyl-5-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]phenyl]-1,3-thiazol-2-amine, Deoxycytidine kinase, SODIUM ION, ... | 著者 | Saez-Ayala, M, Ben-Yaala, K, Betzi, S, Rebuffet, E, Morelli, X. | 登録日 | 2022-04-07 | 公開日 | 2023-06-07 | 最終更新日 | 2024-02-07 | 実験手法 | X-RAY DIFFRACTION (2 Å) | 主引用文献 | From a drug repositioning to a structure-based drug design approach to tackle acute lymphoblastic leukemia. Nat Commun, 14, 2023
|
|
7ZI7
| Crystal structure of dCK C4S-S74E mutant in complex with UDP and the OR0345 inhibitor | 分子名称: | 4-(4-azanylpyrimidin-2-yl)-N-[2-methyl-5-[4-[2-(4-methylpiperazin-1-yl)ethyl]phenyl]phenyl]-N-propyl-1,3-thiazol-2-amine, Deoxycytidine kinase, SODIUM ION, ... | 著者 | Saez-Ayala, M, Ben-Yaala, K, Betzi, S, Rebuffet, E, Morelli, X. | 登録日 | 2022-04-07 | 公開日 | 2023-06-07 | 最終更新日 | 2024-02-07 | 実験手法 | X-RAY DIFFRACTION (1.8 Å) | 主引用文献 | From a drug repositioning to a structure-based drug design approach to tackle acute lymphoblastic leukemia. Nat Commun, 14, 2023
|
|
7ZI9
| Crystal structure of dCK C4S-S74E mutant in complex with UDP and the OR0624 inhibitor | 分子名称: | 2-[2-[[2-methyl-5-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]phenyl]-propyl-amino]-1,3-thiazol-4-yl]pyrimidine-4,6-diamine, Deoxycytidine kinase, SODIUM ION, ... | 著者 | Saez-Ayala, M, Ben-Yaala, K, Betzi, S, Rebuffet, E, Morelli, X. | 登録日 | 2022-04-07 | 公開日 | 2023-06-07 | 最終更新日 | 2024-02-07 | 実験手法 | X-RAY DIFFRACTION (1.8 Å) | 主引用文献 | From a drug repositioning to a structure-based drug design approach to tackle acute lymphoblastic leukemia. Nat Commun, 14, 2023
|
|
7ZI2
| Crystal structure of dCK C4S-S74E mutant in complex with UDP and the dCKi2 inhibitor | 分子名称: | Deoxycytidine kinase, N-[3-[[4-[4,6-bis(azanyl)pyrimidin-2-yl]-1,3-thiazol-2-yl]amino]-4-methyl-phenyl]-4-[(4-methylpiperazin-1-yl)methyl]benzamide, SODIUM ION, ... | 著者 | Saez-Ayala, M, Ben-Yaala, K, Betzi, S, Rebuffet, E, Morelli, X. | 登録日 | 2022-04-07 | 公開日 | 2023-06-07 | 最終更新日 | 2024-02-07 | 実験手法 | X-RAY DIFFRACTION (2.18 Å) | 主引用文献 | From a drug repositioning to a structure-based drug design approach to tackle acute lymphoblastic leukemia. Nat Commun, 14, 2023
|
|
7ZI8
| Crystal structure of dCK C4S-S74E mutant in complex with UDP and the OR0602 inhibitor | 分子名称: | 2-[2-[[2-methyl-5-[6-[2-(4-methylpiperazin-1-yl)ethyl]pyridin-3-yl]phenyl]-propyl-amino]-1,3-thiazol-4-yl]pyrimidine-4,6-diamine, Deoxycytidine kinase, SODIUM ION, ... | 著者 | Saez-Ayala, M, Ben-Yaala, K, Betzi, S, Rebuffet, E, Morelli, X. | 登録日 | 2022-04-07 | 公開日 | 2023-06-07 | 最終更新日 | 2024-02-07 | 実験手法 | X-RAY DIFFRACTION (1.99 Å) | 主引用文献 | From a drug repositioning to a structure-based drug design approach to tackle acute lymphoblastic leukemia. Nat Commun, 14, 2023
|
|
8OOJ
| Crystal structure of dCK C4S-S74E mutant in complex with EdC and UDP | 分子名称: | 4-azanyl-1-[(2~{R},4~{S},5~{R})-5-ethynyl-5-(hydroxymethyl)-4-oxidanyl-oxolan-2-yl]pyrimidin-2-one, Deoxycytidine kinase, URIDINE-5'-DIPHOSPHATE | 著者 | Saez-Ayala, M, Rebuffet, E, Betzi, S, Morelli, X. | 登録日 | 2023-04-05 | 公開日 | 2023-12-20 | 最終更新日 | 2024-05-15 | 実験手法 | X-RAY DIFFRACTION (2.1 Å) | 主引用文献 | 4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress. Mol.Cancer Ther., 23, 2024
|
|
5MQJ
| Crystal structure of dCK mutant C3S | 分子名称: | 2'-DEOXYURIDINE 5'-MONOPHOSPHATE, Deoxycytidine kinase, MAGNESIUM ION, ... | 著者 | Saez-Ayala, M, Rebuffet, E, Hammam, K, Gros, L, Lopez, S, Hajem, B, Humbert, M, Baudelet, E, Audebert, S, Betzi, S, Lugari, A, Combes, S, Pez, D, Letard, S, Mansfield, C, Moussy, A, de Sepulveda, P, Morelli, X, Dubreuil, P. | 登録日 | 2016-12-20 | 公開日 | 2017-11-22 | 最終更新日 | 2024-01-17 | 実験手法 | X-RAY DIFFRACTION (3.7 Å) | 主引用文献 | Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology. Nat Commun, 8, 2017
|
|
5MQT
| Crystal structure of dCK mutant C3S in complex with imatinib and UDP | 分子名称: | 2'-DEOXYCYTIDINE-5'-MONOPHOSPHATE, 4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE, Deoxycytidine kinase, ... | 著者 | Saez-Ayala, M, Rebuffet, E, Hammam, K, Gros, L, Lopez, S, Hajem, B, Humbert, M, Baudelet, E, Audebert, S, Betzi, S, Lugari, A, Combes, S, Pez, D, Letard, S, Mansfield, C, Moussy, A, de Sepulveda, P, Morelli, X, Dubreuil, P. | 登録日 | 2016-12-20 | 公開日 | 2017-11-22 | 最終更新日 | 2024-01-17 | 実験手法 | X-RAY DIFFRACTION (3.2 Å) | 主引用文献 | Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology. Nat Commun, 8, 2017
|
|
7ZI3
| Crystal structure of dCK C4S-S74E mutant in complex with UDP and the OR0642 inhibitor | 分子名称: | 2-[2-[[2-methyl-5-[4-(4-methylpiperazin-1-yl)sulfonyl-2-(trifluoromethyl)phenyl]phenyl]-propyl-amino]-1,3-thiazol-4-yl]pyrimidine-4,6-diamine, Deoxycytidine kinase, SODIUM ION, ... | 著者 | Ben-Yaala, K, Saez-Ayala, M, Betzi, S, Rebuffet, E, Morelli, X. | 登録日 | 2022-04-07 | 公開日 | 2023-06-07 | 最終更新日 | 2024-02-07 | 実験手法 | X-RAY DIFFRACTION (1.9 Å) | 主引用文献 | From a drug repositioning to a structure-based drug design approach to tackle acute lymphoblastic leukemia. Nat Commun, 14, 2023
|
|
7ZIA
| Crystal structure of dCK C4S-S74E mutant in complex with UDP and the OR0634 inhibitor | 分子名称: | 2-[2-[[2-methyl-5-[6-(4-methylpiperazin-1-yl)sulfonylpyridin-3-yl]phenyl]-propyl-amino]-1,3-thiazol-4-yl]pyrimidine-4,6-diamine, Deoxycytidine kinase, SODIUM ION, ... | 著者 | Ben-Yaala, K, Saez-Ayala, M, Betzi, S, Rebuffet, E, Morelli, X. | 登録日 | 2022-04-07 | 公開日 | 2023-06-07 | 最終更新日 | 2024-02-07 | 実験手法 | X-RAY DIFFRACTION (1.7 Å) | 主引用文献 | From a drug repositioning to a structure-based drug design approach to tackle acute lymphoblastic leukemia. Nat Commun, 14, 2023
|
|
7ZIB
| Crystal structure of dCK C4S-S74E mutant in complex with UDP and the OR0635 inhibitor | 分子名称: | 2-[2-[[5-[3-methoxy-4-(4-methylpiperazin-1-yl)sulfonyl-phenyl]-2-methyl-phenyl]-propyl-amino]-1,3-thiazol-4-yl]pyrimidine-4,6-diamine, Deoxycytidine kinase, SODIUM ION, ... | 著者 | Ben-Yaala, K, Saez-Ayala, M, Betzi, S, Rebuffet, E, Morelli, X. | 登録日 | 2022-04-07 | 公開日 | 2023-06-07 | 最終更新日 | 2024-02-07 | 実験手法 | X-RAY DIFFRACTION (1.95 Å) | 主引用文献 | From a drug repositioning to a structure-based drug design approach to tackle acute lymphoblastic leukemia. Nat Commun, 14, 2023
|
|
5MQL
| Crystal structure of dCK mutant C3S in complex with masitinib and UDP | 分子名称: | 2'-DEOXYCYTIDINE-5'-MONOPHOSPHATE, Deoxycytidine kinase, MAGNESIUM ION, ... | 著者 | Rebuffet, E, Hammam, K, Saez-Ayala, M, Gros, L, Lopez, S, Hajem, B, Humbert, M, Baudelet, E, Audebert, S, Betzi, S, Lugari, A, Combes, S, Pez, D, Letard, S, Mansfield, C, Moussy, A, de Sepulveda, P, Morelli, X, Dubreuil, P. | 登録日 | 2016-12-20 | 公開日 | 2017-11-22 | 最終更新日 | 2024-01-17 | 実験手法 | X-RAY DIFFRACTION (3.25 Å) | 主引用文献 | Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology. Nat Commun, 8, 2017
|
|
7Q3F
| Bromodomain-containing 4 BD1 in complex with the inhibitor CRCM5484 | 分子名称: | 2-[[11-ethanoyl-4-(furan-2-ylmethyl)-3-oxidanylidene-8-thia-4,6,11-triazatricyclo[7.4.0.0^{2,7}]trideca-1(9),2(7),5-trien-5-yl]sulfanyl]-~{N}-(2-methylpyridin-3-yl)ethanamide, Bromodomain-containing protein 4 | 著者 | Carrasco, K, Betzi, S, Morelli, X. | 登録日 | 2021-10-27 | 公開日 | 2022-04-20 | 最終更新日 | 2024-01-31 | 実験手法 | X-RAY DIFFRACTION (1.21 Å) | 主引用文献 | CRCM5484: A BET-BDII Selective Compound with Differential Anti-leukemic Drug Modulation J.Med.Chem., 65, 2022
|
|
7Q5O
| Bromodomain-containing 2 BD2 in complex with the inhibitor CRCM5484 | 分子名称: | 1,2-ETHANEDIOL, 2-[[11-ethanoyl-4-(furan-2-ylmethyl)-3-oxidanylidene-8-thia-4,6,11-triazatricyclo[7.4.0.0^{2,7}]trideca-1(9),2(7),5-trien-5-yl]sulfanyl]-~{N}-(2-methylpyridin-3-yl)ethanamide, Bromodomain-containing protein 2 | 著者 | Carrasco, K, Betzi, S, Morelli, X. | 登録日 | 2021-11-04 | 公開日 | 2022-04-20 | 最終更新日 | 2024-01-31 | 実験手法 | X-RAY DIFFRACTION (1.519 Å) | 主引用文献 | CRCM5484: A BET-BDII Selective Compound with Differential Anti-leukemic Drug Modulation J.Med.Chem., 65, 2022
|
|
4C6A
| High Resolution Structure of the Nucleoside diphosphate kinase | 分子名称: | DI(HYDROXYETHYL)ETHER, NUCLEOSIDE DIPHOSPHATE KINASE, CYTOSOLIC | 著者 | Priet, S, Ferron, F, Alvarez, K, Verron, M, Canard, B. | 登録日 | 2013-09-18 | 公開日 | 2013-11-20 | 最終更新日 | 2023-12-20 | 実験手法 | X-RAY DIFFRACTION (1.25 Å) | 主引用文献 | Enzymatic Synthesis of Acyclic Nucleoside Thiophosphonate Diphosphates: Effect of the Alpha-Phosphorus Configuration on HIV-1 RT Activity. Antiviral Res., 117, 2015
|
|
4CP5
| ndpK in complex with (Rp)-SPMPApp | 分子名称: | NUCLEOSIDE DIPHOSPHATE KINASE, CYTOSOLIC, [[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-sulfanyl-phosphoryl] phosphono hydrogen phosphate | 著者 | Priet, S, Ferron, F, Alvarez, K, Verron, M, Canard, B. | 登録日 | 2014-01-31 | 公開日 | 2015-02-11 | 最終更新日 | 2023-12-20 | 実験手法 | X-RAY DIFFRACTION (2.32 Å) | 主引用文献 | Enzymatic Synthesis of Acyclic Nucleoside Thiophosphonate Diphosphates: Effect of the Alpha-Phosphorus Configuration on HIV-1 RT Activity. Antiviral Res., 117, 2015
|
|